DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/698njl/t_cell_receptor) has announced the addition of the "T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014" report to their offering.
Stimulation of the T cell receptor leads to the activation of NFkB and NFAT signaling modules which play a key role in T cell receptor signaling.
There are today 242 companies plus partners developing 339 T cell receptor pathway targeting drugs in 1232 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 173 drugs.
T-Cell Receptor Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 201 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 196 out of the 199 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 46 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
- Includes more than 242 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Drug name & Synonyms
- Lists commercial, generic and code names for drugs.
- This Drug Pipeline Update contains 339 T cell receptor pathway targeting drugs in development, which have a total of 1232 developmental projects in cancer. In addition there are suspended and ceased drugs.
Pipeline Breakdown According to Number of Drugs
- Marketed # 34
- Registered # 1
- Pre-registration # 3
- Phase III # 38
- Phase II # 113
- Phase I # 155
- Preclinical # 167
- No Data # 4
- Suspended # 6
- Ceased # 173
- Included T cell receptor pathway targeting drugs are also in development for 175 other indications, where of 116 are different cancer indications.
For more information visit http://www.researchandmarkets.com/research/698njl/t_cell_receptor